Acurx Pharmaceuticals, Inc. (ACXP): Nasdaq/NYSE listing notice — Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period

Acurx Pharmaceuticals, Inc.

Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.
If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.
No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.
Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Acurx Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 24, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “ACXP” at this time. In accordance with Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-017437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.